These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 31482428)

  • 1. Prediction of outcome in anal squamous cell carcinoma using radiomic feature analysis of pre-treatment FDG PET-CT.
    Brown PJ; Zhong J; Frood R; Currie S; Gilbert A; Appelt AL; Sebag-Montefiore D; Scarsbrook A
    Eur J Nucl Med Mol Imaging; 2019 Dec; 46(13):2790-2799. PubMed ID: 31482428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Training and external validation of pre-treatment FDG PET-CT-based models for outcome prediction in anal squamous cell carcinoma.
    Frood R; Mercer J; Brown P; Appelt A; Mistry H; Kochhar R; Scarsbrook A
    Eur Radiol; 2024 May; 34(5):3194-3204. PubMed ID: 37924344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined PET-CT and MRI for response evaluation in patients with squamous cell anal carcinoma treated with curative-intent chemoradiotherapy.
    Adusumilli P; Elsayed N; Theophanous S; Samuel R; Cooper R; Casanova N; Tolan DJ; Gilbert A; Scarsbrook AF
    Eur Radiol; 2022 Aug; 32(8):5086-5096. PubMed ID: 35274187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic utility of pre- and post-treatment FDG-PET parameters in anal squamous cell carcinoma.
    Duimering A; Riauka T; Nijjar Y; Ghosh S; MacEwan R; Warkentin H; Schiller D; Tankel K; Usmani N; Severin D; Nijjar T; Fairchild A; Mulder K; Doll C; Wong C; Joseph K
    Radiother Oncol; 2019 Jul; 136():21-28. PubMed ID: 31015125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Machine learning-based FDG PET-CT radiomics for outcome prediction in larynx and hypopharynx squamous cell carcinoma.
    Zhong J; Frood R; Brown P; Nelstrop H; Prestwich R; McDermott G; Currie S; Vaidyanathan S; Scarsbrook AF
    Clin Radiol; 2021 Jan; 76(1):78.e9-78.e17. PubMed ID: 33036778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre- and post-treatment FDG PET-CT as a predictor of patient outcomes in anal squamous cell carcinoma: A systematic review and meta-analysis.
    Mac Curtain BM; Qian W; Bell J; O'Mahony A; Temperly HC; Ng ZQ
    J Med Imaging Radiat Oncol; 2023 Sep; 67(6):634-646. PubMed ID: 37573606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A common [18F]-FDG PET radiomic signature to predict survival in patients with HPV-induced cancers.
    Niyoteka S; Seban RD; Rouhi R; Scarsbrook A; Genestie C; Classe M; Carré A; Sun R; La Greca Saint-Esteven A; Chargari C; McKenna J; McDermott G; Malinen E; Tanadini-Lang S; Guckenberger M; Guren MG; Lemanski C; Deutsch E; Robert C
    Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):4010-4023. PubMed ID: 37632562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of tumour burden assessed by metabolic tumour volume on FDG PET/CT in anal canal cancer.
    Gauthé M; Richard-Molard M; Fayard J; Alberini JL; Cacheux W; Lièvre A
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):63-70. PubMed ID: 27503193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anal cancer chemoradiotherapy outcome prediction using
    Rusten E; Rekstad BL; Undseth C; Klotz D; Hernes E; Guren MG; Malinen E
    Br J Radiol; 2019 May; 92(1097):20181006. PubMed ID: 30810343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer.
    Winton Ed; Heriot AG; Ng M; Hicks RJ; Hogg A; Milner A; Leong T; Fay M; MacKay J; Drummond E; Ngan SY
    Br J Cancer; 2009 Mar; 100(5):693-700. PubMed ID: 19259091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of 18F-FDG PET-derived parameters for predicting complete response to chemoradiotherapy in squamous cell anal carcinoma.
    Filippi L; Fontana A; Spinelli GP; Rossi L; Bagni O
    Nucl Med Commun; 2020 Oct; 41(10):1089-1094. PubMed ID: 32732599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiomic feature analysis of pre-treatment FDG PET-CT for predicting outcome in anal squamous cell carcinoma.
    Li X; Xia Z; Li W
    Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2733-2734. PubMed ID: 32277248
    [No Abstract]   [Full Text] [Related]  

  • 13. Introducing FDG PET/CT-guided chemoradiotherapy for stage III NSCLC in low- and middle-income countries: preliminary results from the IAEA PERTAIN trial.
    Konert T; Vogel WV; Paez D; Polo A; Fidarova E; Carvalho H; Duarte PS; Zuliani AC; Santos AO; Altuhhova D; Karusoo L; Kapoor R; Sood A; Khader J; Al-Ibraheem A; Numair Y; Abubaker S; Soydal C; Kütük T; Le TA; Canh NX; Bieu BQ; Ha LN; Belderbos JSA; MacManus MP; Thorwarth D; Hanna GG
    Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2235-2243. PubMed ID: 31367906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and validation of an [
    Takahashi N; Tanaka S; Umezawa R; Takanami K; Takeda K; Yamamoto T; Suzuki Y; Katsuta Y; Kadoya N; Jingu K
    Acta Oncol; 2023 Feb; 62(2):159-165. PubMed ID: 36794365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of
    Houard C; Pinaquy JB; Mesguich C; Henriques de Figueiredo B; Cazeau AL; Allard JB; Laharie H; Bordenave L; Fernandez P; Vendrely V
    J Nucl Med; 2017 Sep; 58(9):1414-1420. PubMed ID: 28280225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CT and FDG-PET radiologic biomarkers in p16+ oropharyngeal squamous cell carcinoma patients treated with definitive chemoradiotherapy.
    Rosen BS; Wilkie JR; Sun Y; Ibrahim M; Casper KA; Miller JE; Chotchutipan T; Stucken CL; Bradford C; Prince MEP; Rosko AJ; Malloy KM; McLean SA; Chinn SB; Shuman AG; Spector ME; Swiecicki PL; Worden FP; Shah JL; Schonewolf CA; Chapman CH; Eisbruch A; Mierzwa ML
    Radiother Oncol; 2021 Feb; 155():174-181. PubMed ID: 33069764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDG-PET parameters predict for recurrence in anal cancer - results from a prospective, multicentre clinical trial.
    Jones MP; Hruby G; Metser U; Sridharan S; Capp A; Kumar M; Gallagher S; Rutherford N; Holder C; Oldmeadow C; Martin J
    Radiat Oncol; 2019 Aug; 14(1):140. PubMed ID: 31387597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma.
    Mayerhoefer ME; Riedl CC; Kumar A; Gibbs P; Weber M; Tal I; Schilksy J; Schöder H
    Eur J Nucl Med Mol Imaging; 2019 Dec; 46(13):2760-2769. PubMed ID: 31286200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of [
    Li K; Sun H; Lu Z; Xin J; Zhang L; Guo Y; Guo Q
    Eur J Radiol; 2018 Sep; 106():160-166. PubMed ID: 30150039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining the radiomic features and traditional parameters of
    Chen YH; Lue KH; Chu SC; Chang BS; Wang LY; Liu DW; Liu SH; Chao YK; Chan SC
    Ann Nucl Med; 2019 Sep; 33(9):657-670. PubMed ID: 31218571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.